Extent and sources of geographic variation in medicare end-stage renal disease expenditures

被引:24
|
作者
Hirth, RA
Tedeschi, PJ
Wheeler, JRC
机构
[1] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Kidnet Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA
关键词
chronic kidney failure; Medicare; costs and cost analysis; physicians' practice patterns;
D O I
10.1053/ajkd.2001.27702
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Geographic variations in practices and expenditures have been widely documented, leading to concerns that care in some regions is clinically suboptimal and/or economically inefficient. Our objectives are to determine the extent and sources of geographic variation in Medicare expenditures per patient with end-stage renal disease (ESRD) per year. The study population Included all patients with ESRD with Medicare as primary payer during 1997 (n = 284,670). Medicare expenditures were summarized at the hospital referral region (HRR) level. Using regression analysis, we estimated the relationship between expenditures and demographics, case mix, dialysis provider characteristics, distribution of patients across renal replacement therapy modalities, standardized hospitalization ratios, and healthcare wages. Spending per patient-year varied threefold across HRRs, ranging from $17,791 to $59,025 (mean, $38,966 +/- $6,774 [SD]). The regression equation explained 80% of this variation. Although several demographic and case-mix indicators that have been related to spending at the individual level were statistically significant predictors of spending at the HRR level, they did not show enough geographic variation to explain a large fraction of spending variation. Rather, patient distributions across renal replacement modalities, hospitalization patterns, and healthcare wages were the most powerful predictors of spending. Compared with Medicare generally, both the mean and SD of ESRD expenditures were approximately seven times larger. The substantial geographic variability in expenditures for patients with ESRD indicates the potential for improving efficiency and quality of care. Interventions designed to increase transplantation rates, ensure access to peritoneal dialysis, and reduce hospitalization appear most promising. (C) 2001 by the National Kidney Foundation, Inc.
引用
收藏
页码:824 / 831
页数:8
相关论文
共 50 条
  • [41] Keloids and end-stage renal disease
    Freedman, BI
    Morrow, MA
    Tuttle, AB
    Igwemezie, BM
    Rich, SS
    Sherertz, EF
    Tuttlea, FNAJANAEB
    [J]. NEPHRON, 1998, 80 (02): : 244 - 246
  • [42] Lipids in end-stage renal disease
    Wanner, C
    [J]. JOURNAL OF NEPHROLOGY, 2002, 15 (02) : 202 - 204
  • [43] Hypertension in end-stage renal disease
    Martínez-Maldonado, M
    [J]. KIDNEY INTERNATIONAL, 1998, 54 : S67 - S72
  • [44] Osteoporosis in end-stage renal disease
    Lindberg, JS
    Moe, SM
    [J]. SEMINARS IN NEPHROLOGY, 1999, 19 (02) : 115 - 122
  • [45] Adiponectin and end-stage renal disease
    Markaki, Anastasia
    Psylinakis, Emmanuel
    Spyridaki, Aspasia
    [J]. HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2016, 15 (03): : 345 - 354
  • [46] IMPACT OF MEDICARE PART D COVERAGE ON HEALTH OUTCOMES IN END-STAGE RENAL DISEASE
    Park, H.
    Rascati, K. L.
    Lawson, K. A.
    Barner, J.
    Richards, K.
    Malone, D. C.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A10 - A10
  • [47] Dialysis for end-stage renal disease
    Hingorani, S
    Watkins, SL
    [J]. CURRENT OPINION IN PEDIATRICS, 2000, 12 (02) : 140 - 145
  • [48] Nutrition in end-stage renal disease
    Ikizler, TA
    Hakim, RM
    [J]. KIDNEY INTERNATIONAL, 1996, 50 (02) : 343 - 357
  • [49] Hyperphosphatemia in end-stage renal disease
    Indridason, OS
    Quarles, LD
    [J]. ADVANCES IN RENAL REPLACEMENT THERAPY, 2002, 9 (03): : 184 - 192
  • [50] Preventing end-stage renal disease
    Mogensen, CE
    [J]. DIABETIC MEDICINE, 1998, 15 (12) : S51 - S56